<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132786">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01874678</url>
  </required_header>
  <id_info>
    <org_study_id>TTYTG0904</org_study_id>
    <nct_id>NCT01874678</nct_id>
  </id_info>
  <brief_title>A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer</brief_title>
  <official_title>A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TTY Biopharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TTY Biopharm</source>
  <oversight_info>
    <authority>Taiwan: Taiwan Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:

        1. Primary Objective:

           To bridge the data of efficacy in term of overall response rate of TS-1 plus cisplatin
           in Taiwanese advanced NSCLC patients from that gained from Japanese population

        2. Secondary Objectives:

      A.  To assess progression free survival B.  To assess overall survival C.  To bridge the
      safety profile by assessing the toxicities and tolerability
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>2 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To assess overall response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess progression free survival To assess overall survival To bridge the safety profile by assessing the toxicities and tolerability</measure>
    <time_frame>2 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To assess progression free survival To assess overall survival To bridge the safety profile by assessing the toxicities and tolerability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-small-cell Lung Cancer (NSCLC)</condition>
  <arm_group>
    <arm_group_label>TS-1/Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-1/Cisplatin</intervention_name>
    <arm_group_label>TS-1/Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presence of at least one measurable disease

          -  performance status of ECOG 0, 1

          -  age between 20 and 74 years at registration

          -  life expectancy of at least 12 weeks

          -  ability to take the oral study medication (TS-1)

          -  voluntarily signed the written informed consent form.

        Exclusion Criteria:

          -  other malignancy with the exception of curative treated non-melanoma skin cancer or
             cervical carcinoma in situ within 5 years prior to the entry of study

          -  previously received chemotherapy or therapy with systemic anti-tumor effect

          -  significant co-morbid medical conditions, including, but not limited to , heart
             failure, renal failure, hepatic failure, hemorrhagic peptic ulcer, mechanical or
             paralytic ileus, or poorly controlled diabetes

          -  fertile women of child-bearing potential unless using a reliable and appropriate
             contraceptive method throughout the treatment period and for three months following
             cessation of treatment

          -  Presence of mental disease or psychotic manifestation

          -  Participation in another clinical trial with any investigational drug within 30 days
             prior to entry

          -  judged ineligible by physicians for participation in the study due to safety concern.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuh-Min Chen, M.D.</last_name>
    <phone>02-2871-2121</phone>
    <phone_ext>3150</phone_ext>
    <email>ymchen@vghtpe.gov.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dalin Tzu Chi General Hospital</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun-Liang Lai, M.D.</last_name>
      <phone>05-264-8000</phone>
      <phone_ext>5246</phone_ext>
      <email>albertla@ms8.hinet.net</email>
    </contact>
    <investigator>
      <last_name>Chun-Liang Lai, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>E-Da Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Feng Wei, M.D.</last_name>
      <phone>07-615-0011</phone>
      <phone_ext>5057</phone_ext>
      <email>ed102746@edah.org.tw</email>
    </contact>
    <investigator>
      <last_name>Yu-Feng Wei, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Te-Chun Hsia, M.D.</last_name>
      <phone>04-22062121</phone>
      <phone_ext>1251</phone_ext>
      <email>derrick.hsia@msn.hinet.net</email>
    </contact>
    <investigator>
      <last_name>Te-Chun Hsia, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gee-Chen Chang, M.D.</last_name>
      <phone>04-23592525</phone>
      <phone_ext>3256</phone_ext>
      <email>august@vghtc.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Gee-Chen Chang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuh-Min Chen, M.D.</last_name>
      <phone>02-2871-2121</phone>
      <phone_ext>3150</phone_ext>
      <email>ymchen@vghtpe.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Yuh-Min Chen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov.tw/TC/index.aspx</url>
    <description>TFDA</description>
  </link>
  <reference>
    <citation>Okamoto I, Yoshioka H, Morita S, Ando M, Takeda K, Seto T, Yamamoto N, Saka H, Asami K, Hirashima T, Kudoh S, Satouchi M, Ikeda N, Iwamoto Y, Sawa T, Miyazaki M, Tamura K, Kurata T, Fukuoka M, Nakagawa K. Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-na√Øve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol. 2010 Dec 20;28(36):5240-6. doi: 10.1200/JCO.2010.31.0326. Epub 2010 Nov 15.</citation>
    <PMID>21079147</PMID>
  </reference>
  <reference>
    <citation>Ichinose Y, Yoshimori K, Sakai H, Nakai Y, Sugiura T, Kawahara M, Niitani H. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res. 2004 Dec 1;10(23):7860-4.</citation>
    <PMID>15585618</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>June 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
